Brief: Abbvie's Telisotuzumab Adizutecan Receives Two Breakthrough Therapy Designations From The U.S. FDA For Crc And Nsclc
07/10/2026 13:47
BRIEF-Abbvie's Telisotuzumab Adizutecan Receives Two Breakthrough Therapy Designations From The U.S. FDA For Crc And Nsclc Oct 7 (Reuters) - AbbVie Inc. ABBV.N:
ABBVIE'S TELISOTUZUMAB ADIZUTECAN (TEMAB-A) RECEIVES TWO BREAKTHROUGH THERAPY DESIGNATIONS FROM THE U.S. FDA FOR CRC AND NSCLC
ABBVIE'S TELISOTUZUMAB ADIZUTECAN (TEMAB-A) RECEIVES TWO BREAKTHROUGH THERAPY DESIGNATIONS FROM THE U.S. FDA FOR CRC AND NSCLC
Source text: ID:nPn23hSsGa
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96